RxDoctor Payments Data

Rhian Davies, DO

Cardiovascular Disease · York, PANPI 1174899702

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $534,327 of the $853,048 with a category attached, or 62.6%. 32 manufacturers reported payments, led by Shockwave Medical, Inc at 29.8% of the total. 2025 is the largest year on record at $337,082, more than ten times the $8,629 reported in 2019. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$853,048in general payments, 2019–2025

Across 1,001 payments — averaging $852.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$254K
  • Teleflex LLC$131K
  • Boston Scientific$122K
  • Medtronic$119K
  • Abiomed$92K
  • Siemens Medical Solutions USA, Inc.$41K
  • plus $95K from 26 others
$196,792in research payments, 2019–2025

Across 43 payments — averaging $4576.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$179K
  • Boston Scientific$16K
  • M.a. Med Alliance S.A.$2K

What the payments were for

  • Consulting fees$164,76319%
  • Speaking & faculty fees$534,32763%
  • Travel & lodging$94,53511%
  • Food & beverage$59,0937%
  • Education$3290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$853,048 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$118,410
Medicare patients
203
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prasugrel Hcl20$1,575
ClopidogrelClopidogrel Bisulfate93$1,027
Isosorbide Mononitrate ErIsosorbide Mononitrate33$548
Atorvastatin Calcium15$455
Metoprolol Succinate21$215
Carvedilol14$59

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →